The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ice
Agree
Ice has become a freudian de-ramper I see;
'2. We have significant cash runaway.'
Cash runway or runaway? That certainly is the question with AVCT.
Who knows but I dare say CC will want to earn some credibility with investors and markets as soon as she possibly can. That's one change for sure.
All of the board represent the shareholders. Anyways Chris seems more commercially focused, I would expect the trials moving forward to represent other companies trials. Avacta tends to go OTT on data analysis which is often not required at this stage in the process. I expect things will be professional but streamlined to get FDA approval, rather than collect as much data as possible. I expect Chris to play the game extremely well with the regulators moving forward.
Ice
I think you’ll find that it’s mainly the chairman that “represents “ the shareholders
And I research a lot of share and always look at the competition as well
Rubbish she represents the shareholders this is not a charity, they are well aware how much the platform is worth, otherwise they wouldn’t have strengthened the negotiation position. Commercial deals will be done to speed up the process. Another thing I forgot to mention is they are ultra confident on precision now, planning to get rid of Dx to concentrate fully on Tx and put that out publicly means they certainly don’t expect this to fail.
Ice
I should think so. I thought you’d given up misconstruing and arguing with everything I post😄😄😄😄
Ice
Whilst Al was on board I agree with you. But the picture regarding commercialisation has changed completely with Chris. She wants this out there asap and will be happy with a well paid role in new company and share options but isn’t interested in a fortune. The money will take a very poor second place to achieving fast development of the drugs. Also she will want to feel very comfortable with the new company and make sure she isn’t sidelined after a few months
Apologies that last post wasn’t directed at me.., 🤦♂️🤦♂️🤦♂️🤦♂️🤣
Look them up yourself I know you are old but we have SeArCH EnGinES NoW, way more researched than you will ever be. You actually think AVA6000 is only worth approximately 300 million (£1). 🤣🤣🤦♂️👌💯
Always good to see a well researched fact based post. Tell me which other cancer treatments and their developments have you researched?
Touk, you really need to do some research on how pharmaceutical deals are done, plus remember current share price has been completely disconnected from reality based on shock placing sentiment, you will see that if a deal is leaked before it is RNS’d. Even a small one will change sentiment here. Plenty of toxic warheads that can take advantage of the platform, worst case scenario they take a deal for AVA6000 and progress the other drugs in house. As for a takeover deal it could happen however we are now competing with ADC’s and what I have seen is the company’s in that space go for billions of USD. Anyways current share price will have no impact on valuation of technology. That will be done in house.
Jc1968
I worked for a well known consultancy in the US for a couple of years. The cheerleaders were the best part of all sporting occasions. Unlike on this BB. One of my PMs was a cheerleader but he also hunted deer at the weekend with a crossbow 🤣🤣
Ice
Shame no one checked the ZRNS for financial accuracy
Ice
Al had little interest in the commercial side other than to fund his baby (=Avacta) to success
Chris has no interest in Avacta she just wants to get an incredible drug out there saving lives. She knows which BP she wants to TO Avacta. The one that will get AVA6000 to market asap and still have the clout to bring through the pipeline. If we get the arm2 results we hope then Avacta is dead. Long live Novartis or whoever. SP won’t come into it. There will be no bidding war. We will be lucky to come out of it with£1 per share and that might come as shares in the new company.
There now I feel better
Longest post yet… .. who has that on the Windy bingo card!! All of the below is hypotheticals from our resident doom merchant.
1. We are progressing commercial discussions.
2. We have significant cash runaway.
3. 2W trial is parallel dosed and still on track to complete 2h 2024.
Not like the statements in the RNS are checked by a Nomad or anything for substance and accuracy.
Loving these hypothetical conversations and scenarios you are doing though, absolutely pointless but do love them. 🤣🤣
Ice: "They are negotiating deals, hint is in the word PROGRESS and they strengthening negotiation position."
Remember when AS said don't worry about funding and smiled? That could have meant " I have done the deal at 50p", so its all done and therefore no need to worry). (Which actually I said at the time before the raise details were known)
Negotiating deals.
"We will give you £100m for the whole company"
CC: No, we will not accept that.
"Come back to us when you are ready to do a deal at a £100m"
So its a negotiation and its progressing. ....When will you wake up....
Its not about straight line depreciation. Again, how can you not understand that the value of AVCT is completely arbitrary?
Until the science is proven and a value can be assigned to it there is not much value.
The science seems to be progressing great, but the cash burn is progressing too. Its a race that so far with the never ending delays, the delivery of the science might come too late to save lth's. That's why its 46p.
All I have said as a generality, is that this is high risk and not to over commit. So far, everything AVCT have done and produced is pure text book stuff of the vast majority of failed small pharma.
Your devotion to the science is ridiculous when you consider what was said and what happened over the LFT, BAMS and ELISA products. All backed by at the time, the science and tests and data,
So continue with your devotion to the science but be aware that the science can fail and also that even if it doesn't LTH's could still end up with little or mothing.
There is obviously the possibility that this all comes good but as Soleboy pointed out, from here pricewise in that scenario good/great gains may be made, but for most here probably not the overall gains that were once hoped for.
The market is not as thick as mince, you might do well to remember that.
A rapid rise through the ranks.
Only appointed Chief Development Officer 3 months ago.
A quality candidate or no one else interested - discuss.
Nice to see this “ Avacta seeks to create long-term shareholder value alongside patient benefit.” putting SH value first and foremost
Message from the new CEO updated today - pity webmaster did not take oppotunity to remove old data on the page .
No consistency across the site website pages - subject matter .
Maybe not a priority -website needs a complete refresh - bit confusing seeing old/new data .
Anyway FYI : https://avacta.com/investors/ceo-welcome/ 0 2024-05-02 08:55 +00:00
https://avacta.com/investors/ceo-welcome/
Great to see some positivity on the board for once, not ramping, just some good well researched comments.
Yes we still have the usual suspects trying to grab the limelight with repeatedly spouting the same old drivel but for once people are not engaging in their sealion antics.
Good times ahead!
GLA
All we are saying...............
Is give Chris a chance.
Hope luck has nothing to do with this. Been here 11 years Waiting
You must type like an experienced secretary as they're long winded to say the least. Bizarre you spend a lot of time posting on a company you just trade in as you do with sometimes 20 others. Each to their own
Statement from RNS.
“Avacta has been able to leverage this excellent progress in the clinic to progress conversations with potential commercial partners.”
They are negotiating deals, hint is in the word PROGRESS and they strengthening negotiation position. What are you even on about the rapid drop was due to the shock placing only. It instantly went down to the 50p price which decimated the 34% discount logically the math doesn’t add up and is sentiment driven. Accounts are done on a 12 month basis the going concern section is generic and doesn’t factor in all variables. They have said this raise significantly increases cash runaway. What’s not to like. Again why are you here? Hero complex? You are not invested anymore so assume just want next entry price then you will shut up and come back when you sell up again!! So transparent. 🙄🙄🥱